Home Featured Page 234

Featured

Latest

Esme Dark – Psychedelics, Somatics and the Shadow

What Approval Won’t Solve: Brian Barnett on Ketamine’s Lessons, RVUs, and Scaling Psychedelic Care

Film Club: Music for Mushrooms

Psychedelic Approvals on Track, Advocacy in Flux: A Washington Dispatch on FDA, Election Year and ‘Ibogaine Exceptionalism’

Red Light Holland Closes Majority Stake in Acadian Exotic Mushrooms, Partnering...

Psyched Wellness Commences Neurobehavioral Preclinical Trial Study on AME-1

No, VR Will Not Give You A Psychedelic Trip

PharmaTher Provides Business Highlights and Releases Annual Financials for Fiscal Year...

Danish And British Startups Partner to Bring Innovative Psychedelics to Patients

Glutamate’s Role in Rapidly-Acting Antidepressants

Mindset Pharma Develops Highly Specialized Preclinical Rodent Trained Studies with Its...

Algernon Pharmaceuticals Confirms DMT Increased Growth of Neurons by 40% in...

Nova Mentis Expands Psilocybin Research Program Targets Obesity and Diabetes

Filament Health Shares to Commence Trading on the OTC Market

EDITOR PICKS

Esme Dark – Psychedelics, Somatics and the Shadow

What Approval Won’t Solve: Brian Barnett on Ketamine’s Lessons, RVUs, and...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Esme Dark – Psychedelics, Somatics and the Shadow

What Approval Won’t Solve: Brian Barnett on Ketamine’s Lessons, RVUs, and Scaling Psychedelic Care

test

Film Club: Music for Mushrooms

Psychedelic Approvals on Track, Advocacy in Flux: A Washington Dispatch on FDA, Election Year and ‘Ibogaine Exceptionalism’

Red Light Holland Closes Majority Stake in Acadian Exotic Mushrooms, Partnering...

Psyched Wellness Commences Neurobehavioral Preclinical Trial Study on AME-1

No, VR Will Not Give You A Psychedelic Trip

PharmaTher Provides Business Highlights and Releases Annual Financials for Fiscal Year...

Danish And British Startups Partner to Bring Innovative Psychedelics to Patients

Glutamate’s Role in Rapidly-Acting Antidepressants

Mindset Pharma Develops Highly Specialized Preclinical Rodent Trained Studies with Its...

Algernon Pharmaceuticals Confirms DMT Increased Growth of Neurons by 40% in...

Nova Mentis Expands Psilocybin Research Program Targets Obesity and Diabetes

Filament Health Shares to Commence Trading on the OTC Market

EDITOR PICKS

Esme Dark – Psychedelics, Somatics and the Shadow

What Approval Won’t Solve: Brian Barnett on Ketamine’s Lessons, RVUs, and...

test

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY